New darpin immunotherapy! Molecular partners mp0250 is qualified as FDA orphan drug to treat multiple myeloma!

December 27, 2019 / BIOON / -- molecular partners is a clinical stage biotechnology company, taking the lead in using darpin ® therapy to treat serious diseases Recently, the company announced that the U.S Food and Drug Administration (FDA) has awarded mp0250 orphan drug qualification (odd) to treat multiple myeloma (mm) Orphan drug (Orphan Drug) is a kind of medicine used for prevention, treatment and diagnosis of rare diseases Rare diseases are a general term for diseases with very low incidence rate, also known as orphan diseases In the United States, rare diseases refer to the types of diseases with a population of less than 200000 Incentives for drug research and development of rare diseases include various incentives for clinical development, such as tax credits related to clinical trial costs, FDA user fee relief, FDA assistance in clinical trial design, and a 7-year market monopoly period for the approved indications after the drug is launched Mp0250 is a first-in-class, tri specific, and multiple darpin ® drug phenology, which can bind and inhibit vascular endothelial growth factor (VEGF) and hepatocyte growth factor (HGF), and combine with human serum albumin (HSA), thus improving plasma half-life By inhibiting the VEGF and HGF pathways, mp0250 may restore the clinical sensitivity of many standard therapies in multiple myeloma (mm) Mp0250's unique mechanism of action represents a new method of targeting tumor microenvironment, which can increase patients' response to approved mm therapy, even after disease progression Although progress has been made in the treatment of multiple myeloma (mm) in recent years, due to the adaptive resistance of cancer to treatment, most patients are still unable to cure mm The escape pathways of VEGF and HGF are closely related to the failure of MM end-line therapy Mp0250 is designed to block the VEGF and HGF pathways, restore the clinical sensitivity to standard nursing therapy, and expand its efficacy Darpin therapy is a new kind of protein therapy, which will open up additional dimensions of multi-specific and multi-functional Darpin candidates include multiple designed anchor protein repeat binding domains that can target up to six or more targets, providing potential benefits compared to conventional monoclonal antibodies or other available protein therapies Darpin technology is a fast and cost-effective discovery engine, which can produce candidate drugs with ideal development characteristics and high production Darpin platform technology can expand the application of traditional protein and antibody methods Darpin therapy is constructed by darpin protein modules These modules are single domain proteins, which are one tenth of the size of complete antibodies They have a constant framework and randomized target binding surface Darpin candidate drugs not only have differential biological activity, but also have ideal therapeutic properties, including very low immunogenicity potential, which can be comparable to antibody, and have no extra target effect At present, this kind of therapy has been verified in a wide range of preclinical and clinical trials, involving as many as 2000 patients (1900 ophthalmic patients and 75 tumor patients) In addition, darpin candidate drugs also have good development performance, including low-cost and high-yield manufacturing and shelf life up to several years at 4 ℃ Original source: molecular partners receive orphan drug design for mp0250 for multiple myeloma